Cybin (FRA:R7E1) Debt-to-Equity : 0.00 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Cybin Debt-to-Equity?

Cybin's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.22 Mil. Cybin's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.03 Mil. Cybin's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €82.86 Mil. Cybin's debt to equity for the quarter that ended in Dec. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cybin's Debt-to-Equity or its related term are showing as below:

FRA:R7E1's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

Cybin Debt-to-Equity Historical Data

The historical data trend for Cybin's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cybin Debt-to-Equity Chart

Cybin Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Debt-to-Equity

Cybin Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial										-	-	-	-	-

Competitive Comparison of Cybin's Debt-to-Equity

For the Biotechnology subindustry, Cybin's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cybin's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cybin's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cybin's Debt-to-Equity falls into.

Cybin Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cybin's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	32.924
	=	0.00

Cybin's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.221	+	0.029)	/	82.856
	=	0.00

Cybin (FRA:R7E1) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Cybin Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Cybin's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cybin (FRA:R7E1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cybin Inc (FRA:R7E1) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

CYBN:USA CYBN:Canada

Address

100 King Street West, Suite 5600, Toronto, ON, CAN, M5X 1C9

Website

https://www.cybin.com

Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds and protocols as potential treatments for various psychiatric and neurological conditions.

Cybin (FRA:R7E1) Headlines

No Headlines